RU2492175C2 - Бензиловые производные гликозидов и способы их применения - Google Patents

Бензиловые производные гликозидов и способы их применения Download PDF

Info

Publication number
RU2492175C2
RU2492175C2 RU2009140298/04A RU2009140298A RU2492175C2 RU 2492175 C2 RU2492175 C2 RU 2492175C2 RU 2009140298/04 A RU2009140298/04 A RU 2009140298/04A RU 2009140298 A RU2009140298 A RU 2009140298A RU 2492175 C2 RU2492175 C2 RU 2492175C2
Authority
RU
Russia
Prior art keywords
pyran
chloro
hydroxymethyl
phenyl
triol
Prior art date
Application number
RU2009140298/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2009140298A (ru
Inventor
Юаньвэй ЧЭНЬ
Янь ФЭН
Байхуа СЮЙ
Бинхуа ЛВ
Брайан СИД
Майкл Дж. ХЭД
Хуавэй ЧЭН
Цзелин ЧЭН
Мин СЮЙ
Цунна ВАН
Цзиань ДУ
Лили ЧЖАН
Гэ СЮЙ
Юэлинь У
Original Assignee
Теракос, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Теракос, Инк. filed Critical Теракос, Инк.
Publication of RU2009140298A publication Critical patent/RU2009140298A/ru
Application granted granted Critical
Publication of RU2492175C2 publication Critical patent/RU2492175C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
    • C07G3/00—Glycosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2009140298/04A 2007-04-02 2008-04-01 Бензиловые производные гликозидов и способы их применения RU2492175C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90967207P 2007-04-02 2007-04-02
US60/909,672 2007-04-02
PCT/US2008/059047 WO2008122014A1 (en) 2007-04-02 2008-04-01 Benzylic glycoside derivatives and methods of use

Publications (2)

Publication Number Publication Date
RU2009140298A RU2009140298A (ru) 2011-05-10
RU2492175C2 true RU2492175C2 (ru) 2013-09-10

Family

ID=39795470

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009140298/04A RU2492175C2 (ru) 2007-04-02 2008-04-01 Бензиловые производные гликозидов и способы их применения

Country Status (16)

Country Link
US (1) US7838498B2 (OSRAM)
EP (1) EP2064222B1 (OSRAM)
JP (1) JP5583003B2 (OSRAM)
KR (1) KR101506935B1 (OSRAM)
CN (2) CN104803957A (OSRAM)
AR (2) AR065913A1 (OSRAM)
AU (1) AU2008232419B2 (OSRAM)
BR (1) BRPI0809607A2 (OSRAM)
CA (1) CA2682202C (OSRAM)
DK (1) DK2064222T3 (OSRAM)
ES (1) ES2466672T3 (OSRAM)
HK (1) HK1212982A1 (OSRAM)
IL (1) IL201065A (OSRAM)
RU (1) RU2492175C2 (OSRAM)
TW (1) TWI405575B (OSRAM)
WO (1) WO2008122014A1 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
AU2009270936B2 (en) * 2008-07-15 2014-12-18 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
CN102177147A (zh) * 2008-08-22 2011-09-07 泰拉科斯有限公司 制备sglt2抑制剂的方法
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
WO2011070592A2 (en) 2009-12-09 2011-06-16 Panacea Biotec Ltd. Novel sugar derivatives
US20110160143A1 (en) * 2009-12-28 2011-06-30 Perricone Nicholas V Topical Acyl Glutathione Psoriasis Compositions
CN102134226B (zh) * 2010-01-26 2013-06-12 天津药物研究院 一类苯基c-葡萄糖苷衍生物、其制备方法和用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
BR112013004882A2 (pt) 2010-08-31 2016-05-03 Snu R&Db Foundation utilização de reprogramação fetal de agonista ppar delta
CN102643256B (zh) * 2011-02-18 2014-12-24 上海璎黎科技有限公司 一种芳基糖苷类化合物及其制备方法和应用
CN102675378A (zh) * 2011-03-09 2012-09-19 天津药物研究院 一类含环丙烷结构的c-葡萄糖苷衍生物、其制备方法和用途
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2755722B1 (en) 2011-09-13 2017-05-24 Panacea Biotec Ltd. Novel sglt inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
CN103910769B (zh) 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2015051484A1 (en) 2013-10-12 2015-04-16 Theracos, Inc. Preparation of hydroxy-benzylbenzene derivatives
CN104387428A (zh) * 2014-12-09 2015-03-04 济南卡博唐生物科技有限公司 一种制备3,5,6-三-氧-苄基-1,2-异丙叉基-d-葡萄糖的方法
CN104478967A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含腈基苯噻唑基的o-半乳糖苷衍生物、其制备方法和用途
WO2017070689A2 (en) 2015-10-23 2017-04-27 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
CN105770861B (zh) * 2016-04-08 2020-02-28 吴一行 一种用于治疗男性糖尿病患者勃起功能障碍的药物
JP7160821B2 (ja) * 2017-02-24 2022-10-25 ドン－ア エスティ カンパニー リミテッド Ｓｇｌｔ－２阻害剤である新規グルコース誘導体
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
CN110551088B (zh) * 2018-06-01 2022-10-21 北京惠之衡生物科技有限公司 氘修饰的苄基-4-氯苯基的c-糖苷衍生物
CN112294787B (zh) * 2020-11-17 2021-10-19 四川大学华西医院 一种治疗肝癌的联合用药物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576592B1 (en) * 1991-03-18 2000-05-31 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US6414126B1 (en) * 1999-10-12 2002-07-02 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
RU2297422C2 (ru) * 2000-12-20 2007-04-20 Шеринг Корпорейшн Замещенные остатком сахара 2-азетидиноны, пригодные для использования в качестве гипохолестеринемических препаратов

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933438A (en) 1984-02-29 1990-06-12 University Of Florida Brain-specific analogues of centrally acting amines
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5312817A (en) 1991-05-14 1994-05-17 Ernir Snorrason Treatment of fatigue syndrome
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
FR2710265B1 (fr) 1993-09-22 1995-10-20 Adir Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs.
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
DE19541260A1 (de) 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6224036B1 (en) 1997-01-17 2001-05-01 Applied Power Inc. Concrete reinforcement cable tensioner
EA002806B1 (ru) 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6248864B1 (en) 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6312717B1 (en) 1998-07-07 2001-11-06 Bristol-Myers Squibb Company Method for treatment of anxiety and depression
US20020009478A1 (en) 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
SE9802864D0 (sv) 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
DE69923200T2 (de) 1998-10-01 2005-12-22 Novartis Ag Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2792527B1 (fr) 1999-04-22 2004-08-13 Ethypharm Lab Prod Ethiques Microgranules de ketoprofene, procede de preparation et compositions pharmaceutiques
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
AU781048B2 (en) 1999-09-02 2005-05-05 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6080736A (en) 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
AU2463701A (en) 1999-12-29 2001-07-09 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6482440B2 (en) 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
AU2002215218A1 (en) * 2000-11-17 2002-05-27 Takeda Chemical Industries Ltd. Isoxazole derivatives
US6524615B2 (en) 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
AU2003254847B2 (en) 2002-08-08 2009-06-04 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
PL372865A1 (en) 2002-08-09 2005-08-08 Taisho Pharmaceutical Co, Ltd. Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
EP1609785B1 (en) * 2003-03-14 2016-02-03 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
JP2004359630A (ja) * 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
US7094763B2 (en) 2003-08-01 2006-08-22 Janssen Pharaceutica, N.V. Substituted fused heterocyclic C-glycosides
AU2004261663A1 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
ES2649737T5 (es) 2003-08-01 2021-07-07 Mitsubishi Tanabe Pharma Corp Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
US7371732B2 (en) 2003-12-22 2008-05-13 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
NZ549629A (en) 2004-03-04 2010-06-25 Kissei Pharmaceutical Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
DE102004012676A1 (de) * 2004-03-16 2005-10-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CN103435581B (zh) 2004-03-16 2015-08-19 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1828216B1 (en) * 2004-12-16 2008-09-10 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
WO2006108842A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576592B1 (en) * 1991-03-18 2000-05-31 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US6414126B1 (en) * 1999-10-12 2002-07-02 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
RU2297422C2 (ru) * 2000-12-20 2007-04-20 Шеринг Корпорейшн Замещенные остатком сахара 2-азетидиноны, пригодные для использования в качестве гипохолестеринемических препаратов

Also Published As

Publication number Publication date
EP2064222A4 (en) 2011-12-14
RU2009140298A (ru) 2011-05-10
HK1212982A1 (zh) 2016-06-24
WO2008122014A1 (en) 2008-10-09
US7838498B2 (en) 2010-11-23
AR110968A2 (es) 2019-05-22
AU2008232419A1 (en) 2008-10-09
JP5583003B2 (ja) 2014-09-03
EP2064222A1 (en) 2009-06-03
JP2010523583A (ja) 2010-07-15
US20080242596A1 (en) 2008-10-02
DK2064222T3 (da) 2014-07-21
TWI405575B (zh) 2013-08-21
ES2466672T3 (es) 2014-06-10
AU2008232419B2 (en) 2013-06-20
AR065913A1 (es) 2009-07-08
EP2064222B1 (en) 2014-05-07
BRPI0809607A2 (pt) 2014-09-30
CN104803957A (zh) 2015-07-29
CA2682202C (en) 2016-01-12
TW200846012A (en) 2008-12-01
CN101652377A (zh) 2010-02-17
IL201065A0 (en) 2010-05-17
CA2682202A1 (en) 2008-10-09
IL201065A (en) 2015-09-24
KR20100016151A (ko) 2010-02-12
KR101506935B1 (ko) 2015-03-31

Similar Documents

Publication Publication Date Title
RU2492175C2 (ru) Бензиловые производные гликозидов и способы их применения
RU2497526C2 (ru) Производные бензилбензола и способы их применения
JP2010523583A5 (OSRAM)
US8642585B2 (en) Indanyloxydihydrobenzofuranylacetic acids
RU2213731C2 (ru) Производные пиперидина и фармацевтическая композиция на их основе
US7977466B2 (en) C-glycoside derivatives and salts thereof
US20140336174A1 (en) Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease
US9744153B2 (en) 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
JP2010536882A5 (OSRAM)
JP2011509922A5 (OSRAM)
CA2534022A1 (en) Di-aryl glycoside derivatives and their use as sglt inhibitors
SI2513053T1 (en) Pyrrolidine carboxylic acid derivatives as G-protein-coupled receptor 43 agonists (GPR43), pharmaceutical composition and methods for use in the treatment of metabolic disorders
JO2784B1 (en) 5,3,1 - Triazole substitute derivative
JP2011506469A5 (OSRAM)
CA2602781A1 (en) 1h-pyrazole 4-carboxylamides, their preparation and their use as 11beta-hydroxysteroid dehydrogenase
WO2012041898A1 (en) Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
WO2021247601A1 (en) Methods and compositions for treating rna viral infections
JPWO2008108486A1 (ja) １−ビアリールアゼチジノン誘導体
JPWO2021071837A5 (OSRAM)
KR20160058886A (ko) 전신 홍반성 낭창 및/또는 낭창성 신염의 예방 또는 치료 방법
RU2021111591A (ru) Кристаллические твердые формы n-(1-((2-(диметиламино)этил)амино)-2-метил-1-оксопропан-2-ил)-4-(4-(2-метил-5-((2s,3r,4r,5s,6r)-3,4,5-тригидрокси-6-(метилтио)тетрагидро-2h-пиран-2-ил)бензил)фенил)бутанамида и способы их синтеза
JP2010083879A (ja) 脂質異常症治療剤
JP2004250455A (ja) 動脈硬化症および黄色腫の予防および治療剤

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200402